Loading clinical trials...
Loading clinical trials...
Safety of Intraarterial Infusion of Adipose Tissue-derived Mesenchymal Stromal Cells to Treat Antibody-mediated and Cellular Rejection in Adult Kidney Transplant Recipients (AMSCAR)
Conditions
Interventions
Low dose adipose tissue derived mesenchymal stromal cells (A-MSC)
High dose adipose tissue derived mesenchymal stromal cells (A-MSC)
Locations
1
United States
Mayo Clinic
Rochester, Minnesota, United States
Start Date
January 30, 2023
Primary Completion Date
April 1, 2026
Completion Date
April 1, 2026
Last Updated
October 14, 2025
NCT05702398
NCT07415421
NCT07006532
NCT07333495
NCT04542733
NCT06958796
Lead Sponsor
Mayo Clinic
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions